Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 21
SponsorMayo Clinic
About this trial
This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.
Eligibility criteria
Qualifiers
Acute lymphoblastic leukemia/lymphoma being treated by the pediatric hematology team
Receiving calaspargase as part of treatment for malignancy
Disqualifiers
Age > 21 years
Patients who are actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab containing arm
Pregnancy
Trial design
Treatments tested in this trial
- Non-Interventional Study
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
1Mayo Clinic in Rochester55905, RochesterMinnesota, United States
Sponsors and collaborators
Mayo Clinic
Lead sponsor
Source ClinicalTrials.gov